Journal Article
Research Support, Non-U.S. Gov't
Add like
Add dislike
Add to saved papers

A tobacco-specific carcinogen, NNK, enhances AOM/DSS-induced colon carcinogenesis in male A/J mice.

In Vivo 2008 September
To determine whether tobacco-derived carcinogens affect colon carcinogenesis, the effects of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) on colon carcinogenesis were examined using an azoxymethane (AOM)/dextran sulfate sodium (DSS) mouse model. NNK (10 micromol) was administered to male A/J mice by a single intraperitoneal (i.p.) injection and then AOM (10 mg/kg body weight, i.p.) was given 1 week after NNK administration. One week later, the mice received 1.5% (w/v) DSS in their drinking water for 7 days. All animals were sacrificed at week 22 to examine the pathological lesions in the colon and lung. The incidence (80%, p < 0.05) and multiplicity (4.0 +/- 3.6, p < 0.05) of colonic tumors of the NNK + AOM + DSS group were significantly higher than that of the AOM + DSS group (incidence, 40%; and multiplicity, 1.2 +/- 1.7). The differences in incidence and multiplicity of lung tumors were insignificant between these two groups. Our findings may suggest that smoking increases the risk of inflammation-related colon cancer development.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app